Huang Ruyi, Wang Xiaochen, Zhang Wenjie, Zhangyuan Guangyan, Jin Kangpeng, Yu Weiwei, Xie Yu, Xu Xiaoliang, Wang Hai, Sun Beicheng
Key Laboratory on Living Donor Liver Transplantation, Ministry of Health, Department of Liver surgery, Collaborative Innovation Center For Cancer Personalized Medicine, First Affiliated Hospital of Nanjing Medical University, Nanjing, P.R. China.
Cell Physiol Biochem. 2016;40(3-4):707-715. doi: 10.1159/000452582. Epub 2016 Nov 30.
BACKGROUND/AIMS: Long non-coding RNAs (lncRNAs) have been reported to play pivotal roles in multiple tumors and can act as tumor biomarkers. In this study, we explored the association of the expression of an lncRNA, DGCR5 with clinicopathological features and prognosis in HCC.
Expression levels of DGCR5 were detected by quantitative real-time PCR (qRT-PCR) and the clinical data was obtained, including basic information, data of clinicopathology and cancer specific survival rate. Receiver operating characteristic (ROC) curve, Kaplan-Meier methods and multivariable Cox regression models were used to analyze predictive efficiency, long-term survival outcomes and risk factors.
DGCR5 was found down-regulated in HCC tissues (P<0.001) and serum (P = 0.0035) and low expression of DGCR5 was correlated with a poor cancer specific survival (CSS) (P = 0.0019), as the overall 5-year CSS rates were 10.3% (low expression group) and 36.6% (high expression group), respectively. A stratified analysis demonstrated that low DGCR5 expression was an independent negative prognostic factor for HCC. In addition, the area under the ROC curve was 0.782 with a sensitivity of 0.633 and a specificity of 0.833.
Our results suggest that DGCR5 may be a participator in HCC and can serve as potential biomarker for the diagnosis and prognosis in HCC.
背景/目的：长链非编码RNA（lncRNAs）已被报道在多种肿瘤中发挥关键作用，并可作为肿瘤生物标志物。在本研究中，我们探讨了lncRNA DGCR5的表达与肝癌临床病理特征及预后的关系。
采用定量实时PCR（qRT-PCR）检测DGCR5的表达水平，并获取临床数据，包括基本信息、临床病理数据和癌症特异性生存率。采用受试者工作特征（ROC）曲线、Kaplan-Meier方法和多变量Cox回归模型分析预测效率、长期生存结果和危险因素。
发现DGCR5在肝癌组织（P<0.001）和血清（P = 0.0035）中表达下调，DGCR5低表达与较差的癌症特异性生存（CSS）相关（P = 0.0019），总体5年CSS率分别为10.3%（低表达组）和36.6%（高表达组）。分层分析表明，DGCR5低表达是肝癌独立的负性预后因素。此外，ROC曲线下面积为0.782，敏感性为0.633，特异性为0.833。
我们的结果表明，DGCR5可能参与肝癌的发生发展，并可作为肝癌诊断和预后的潜在生物标志物。
